At Acadia, we remain deeply committed to providing important new therapies to patients and delivering value for our stockholders. Our Investor Center is designed to provide you with convenient access to company information.

Recent News

- Patients previously treated with 34 mg showed sustained response - Patients on investigational doses and placebo demonstrated symptom improvement when switched to 34 mg dose during OLE SAN DIEGO --(BUSINESS WIRE)--Jun. 3, 2021-- Acadia Pharmaceuticals Inc.
SAN DIEGO --(BUSINESS WIRE)--May 26, 2021-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following investor conferences: Jefferies 2021 Virtual Healthcare Conference Fireside Chat Presentation: Wednesday, June 2, 2021 at 1:30 p.m.
- 1Q21 net sales of $106.6 million , an 18% increase over 1Q20 - Reiterating FY21 net sales guidance of $510 to $550 million SAN DIEGO --(BUSINESS WIRE)--May 5, 2021-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2021 .